A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Official Title

A Phase 1b/2a Two-Part Open-Label Multicentre Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer


The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumours.

Trial Description

Primary Outcome:

  • Maximum Tolerated Dose(s)
Secondary Outcome:
  • Number of dose limiting toxicities (DLTs)
  • Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)
  • Peak plasma concentration (Cmax)
  • Time to reach maximum plasma concentration (tmax)
  • Change from baseline in white blood cell count
  • Change from baseline in neutrophil count
  • Change from baseline in lymphocyte count
  • Number of participants with tumour response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumours (RECIST v.1.1)
  • Duration of objective response
  • Best response
  • Progression free survival
  • Overall survival

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society